Skip to main content
NCBI home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2014 Feb 22;82(2):250–266. doi: 10.1093/jurban/jti049

Illicit opioid use in Canada: Comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study)

Benedikt Fischer 1,✉, Jürgen Rehm 1, Suzanne Brissette 2, Serge Brochu 3, Julie Bruneau 2, Nady El-Guebaly 4, Lina Noël 5, Mark Tyndall 6, Cameron Wild 7, Phil Mun 9, Dolly Baliunas 8
PMCID: PMC3456573  PMID: 15872194

Abstract

Most of the estimated 125,000 injection drug users (IDUs) in Canada use illicit opioids and are outside treatment (i.e., methadone maintenance treatment). Empirical data suggest that illicit opioid users outside treatment are characterized by various health and social problem characteristics, including polydrug use, physical and mental morbidity, social marginalization, and crime. Although required for evidence-based programming, systematic information on this specific substance-user population is sparse in Canada to date. This article presents and compares key characteristics of population of illicit opioid users outside treatment in five cities across Canada (OPICAN cohort). Overall, the majority of OPICAN participants regularly used both a variety of illicit opioids and cocaine or crack, reported physical and mental health (e.g., mood disorder) problems, lacked permanent housing, were involved in crime, and had their “ideal” treatment not available to them. However, key local sample differences were shown, including patterns of heroin versus prescription opioid use and levels of additional cocaine versus crack use as well as indicators of social marginalization. Illicit opioid user population across Canada differ on key social, health, and drug use indicators that are crucial for interventions and are often demonstrated between larger and smaller city sites. Differentiated interventions are required.

Keywords: Canada, Comorbidity, Dependence, Health, Heroin use, Illicit opioid use, Infectious disease, Methadone treatment, Polydrug use, Treatment

Full Text

The Full Text of this article is available as a PDF (126.2 KB).

References

  • 1.Remis R, Leclerc P, Routledge R, et al. Consortium to Characterize Injection Drug Users in Canada (Montreal, Toronto and Vancouver). Final report: Toronto. 1998
  • 2.Fischer B, Rehm J. The case for a heroin substitution treatment trial in Canada. Can J Public Health. 1997;88:367–370. doi: 10.1007/BF03403907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Fischer B, Medved W, Gliksman L, Rehm J. Illicit opiates in Toronto: a profile of current users. Addict Res. 1999;7:377–415. doi: 10.3109/16066359909004395. [DOI] [Google Scholar]
  • 4.Brands B, Blake J, Marsh D. Changing patient characteristics with increased methadone maintenance availability. Drug Alcohol Depend. 2002;66:11–20. doi: 10.1016/S0376-8716(01)00176-4. [DOI] [PubMed] [Google Scholar]
  • 5.Perreault M, Rousseau M, Mercier C, Lauzon P, Gagnon C, Cote P. Accessibility to methadone substitution treatment and reduction of damaging effects. The role of the Montreal low-threshold methadone program. Can J Public Health. 2003;94:197–200. doi: 10.1007/BF03405066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lehmann F, Lauzon P, Amsel R. Methadone maintenance: predictors of outcome in a Canadian milieu. J Subst Abuse Treat. 1993;10:85–89. doi: 10.1016/0740-5472(93)90104-A. [DOI] [PubMed] [Google Scholar]
  • 7.Strathdee S, Patrick D, Currie S, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11:F59–F65. doi: 10.1097/00002030-199708000-00001. [DOI] [PubMed] [Google Scholar]
  • 8.Lamothe F, Vincelette J, Bruneau J, et al. Prevalence, seroconversion rates and risk factors for hepatitis B core, hepatitis C and HIV antibodies among intravenous drug users (IDU) of the Saint-Luc Cohort. 6th Annual Canadian Conference on HIV/AIDS Research, May 1997. Can J Infect Dis. 1997;8:28A–28A. [Google Scholar]
  • 9.Fischer B, Rehm J, Blitz-Miller T. Injection drug use and preventive measures: a comparison of Canadian and Western European jurisdictions over time. CMAJ. 2000;162:1709–1713. [PMC free article] [PubMed] [Google Scholar]
  • 10.Patrick D, Tyndall M, Cornelisse P, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ. 2001;165:889–895. [PMC free article] [PubMed] [Google Scholar]
  • 11.Hankins C, Alary M, Parent R, Blanchette C, Claessens C, the SurvUDI Working Group Continuing HIV transmission among injection drug users in Eastern central Canada: The SurvUDI Study, 1995–2001. J Acquir Immune Defic Syndr. 2002;30:514–521. doi: 10.1097/00126334-200208150-00007. [DOI] [PubMed] [Google Scholar]
  • 12.Bruneau J, Lamothe F, Franco E, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol. 1997;146:994–1002. doi: 10.1093/oxfordjournals.aje.a009240. [DOI] [PubMed] [Google Scholar]
  • 13.Vader J, Hammig R, Besson J, Eastus C, Eggenberger C, Burnand B. Appropriateness of methadone maintenance treatment for opiate addiction: evaluation by an expert panel. Soz Praventivmed. 2003;48:S1–S14. doi: 10.1007/s00038-003-4811-7. [DOI] [PubMed] [Google Scholar]
  • 14.Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet. 2001;358:1417–1420. doi: 10.1016/S0140-6736(01)06529-1. [DOI] [PubMed] [Google Scholar]
  • 15.van den Brink W, Hendriks V, van Ree J. Medical co-prescription of heroin to chronic, treatment-resistant methadone patients in the Netherlands. J Drug Issues. 1999;29:587–608. [Google Scholar]
  • 16.Digiusto E, Mattick R, Kimber J, et al. National evaluation of pharmacotherapies for opioid dependence-why have we done it? Drug Alcohol Rev. 2001;20:139–141. doi: 10.1080/09595230120058524. [DOI] [Google Scholar]
  • 17.World Health Organization. The World Health Report 2002: Reducing risks, Promoting Healthy Life. 2002, Geneva. [DOI] [PubMed]
  • 18.Ezzati M, Lopez A, Rodgers A, Vander Horn S, Murray C. The Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–1360. doi: 10.1016/S0140-6736(02)11403-6. [DOI] [PubMed] [Google Scholar]
  • 19.Zou S, Tepper M, Giulivi A. Current status of hepatitis C in Canada. Can J Public Health. 2000;91:S10–S21. doi: 10.1007/BF03405100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wall R, Rehm J, Fischer B, et al. The social cost of untreated opiate use. J Urban Health. 2001;77:688–722. doi: 10.1007/BF02344032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Fischer B, Rehm J, Kirst M, et al. Heroin-assisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health. 2002;12:228–234. doi: 10.1093/eurpub/12.3.228. [DOI] [PubMed] [Google Scholar]
  • 22.Oppenheimer E, Tobutt C, Taylor C, Andrews T. Death and survival in a cohort of heroin addicts at London clinics: a 22 year follow-up study. Addiction. 1994;89:1299–1308. doi: 10.1111/j.1360-0443.1994.tb03309.x. [DOI] [PubMed] [Google Scholar]
  • 23.Seal K, Kral A, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998–99. Am J Public Health. 2001;19:1842–1846. doi: 10.2105/AJPH.91.11.1842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Darke S, Zador D. Fatal heroin ‘overdose’: a review. Addiction. 1996;91:1765–1772. doi: 10.1111/j.1360-0443.1996.tb03800.x. [DOI] [PubMed] [Google Scholar]
  • 25.Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction. 2001;96:1113–1125. doi: 10.1046/j.1360-0443.2001.96811135.x. [DOI] [PubMed] [Google Scholar]
  • 26.Coutinho R. HIV and hepatitis C among injection drug users. BMJ. 1998;317:424–425. doi: 10.1136/bmj.317.7156.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health. 2001;11:425–430. doi: 10.1093/eurpub/11.4.425. [DOI] [PubMed] [Google Scholar]
  • 28.Griffiths P, Gossop M, Powis B, Strang J. Transitions in patterns of heroin administration: a study of heroin chasers and heroin injectors. Addiction. 1994;89:301–309. doi: 10.1111/j.1360-0443.1994.tb00896.x. [DOI] [PubMed] [Google Scholar]
  • 29.van Ameijden E, van den Hoek J, Hartgers C, Coutinho R. Risk factors for the transition from non-injection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol. 1994;139:1153–1163. doi: 10.1093/oxfordjournals.aje.a116962. [DOI] [PubMed] [Google Scholar]
  • 30.Neagius A, Miller M, Friedman S, et al. Potential risk factors for the transition to injection among non-injecting heroin users: a comparison of former injectors and never injectors. Addiction. 2001;96:847–860. doi: 10.1046/j.1360-0443.2001.9668476.x. [DOI] [PubMed] [Google Scholar]
  • 31.Beswick R, Best D, Rees S, Coomber R, Gossop M, Strang J. Multiple drug use: patterns and practices of heroin and crack use in a population of opiate addicts in treatment. Drug Alcohol Rev. 2001;20:201–204. doi: 10.1080/09595230120058588. [DOI] [Google Scholar]
  • 32.Strain E. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002;18:S14–S27. doi: 10.1097/00002508-200207001-00003. [DOI] [PubMed] [Google Scholar]
  • 33.Brooner R, King V, Kidorf M, Schmidt CJ, Bigelow G. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71–80. doi: 10.1001/archpsyc.1997.01830130077015. [DOI] [PubMed] [Google Scholar]
  • 34.Darke S, Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997;48:135–141. doi: 10.1016/S0376-8716(97)00117-8. [DOI] [PubMed] [Google Scholar]
  • 35.Hall W, Bell J, Carless J. Crime and drug use among applicants for methadone maintenance. Drug Alcohol Depend. 1993;31:123–129. doi: 10.1016/0376-8716(93)90064-W. [DOI] [PubMed] [Google Scholar]
  • 36.Nurco D. A long-term program of research on drug use and crime. Subst Use Misuse. 1998;33:1817–1837. doi: 10.3109/10826089809059323. [DOI] [PubMed] [Google Scholar]
  • 37.National Institutes of Health National consensus development panel on effective medical treatment of opiate addiction. JAMA. 1998;280:1936–1943. doi: 10.1001/jama.280.22.1936. [DOI] [PubMed] [Google Scholar]
  • 38.Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT: a review of historical and clinical issues. Mt Sinai J Med. 2000;67:347–364. [PubMed] [Google Scholar]
  • 39.Ward J, Hall W, Mattick R. Role of methadone maintenance in opioid dependence. Lancet. 1999;353:221–226. doi: 10.1016/S0140-6736(98)05356-2. [DOI] [PubMed] [Google Scholar]
  • 40.Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci. 1995;245:114–124. doi: 10.1007/BF02190738. [DOI] [PubMed] [Google Scholar]
  • 41.Strike C, Urbanoski K, Fischer B, Marsh D, Millson P. Increases in methadone maintenance treatment in Ontario, 1996–2001. J Subst Abuse Treat. 2005;24:39–52. doi: 10.1300/J069v24n01_04. [DOI] [PubMed] [Google Scholar]
  • 42.Fischer B. Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. J Public Health Policy. 2000;21:187–210. doi: 10.2307/3343343. [DOI] [PubMed] [Google Scholar]
  • 43.Fischer B, Bisceglia D, Daniel N, Gliksman L. Methadone treatment in Ontario—Results of a physician survey. Ann Med Interne. 2002;153:2S11–2S21. [PubMed] [Google Scholar]
  • 44.Anderson J, Warren L. Client retention in the British Columbia methadone program, 1996–99. Can J Public Health. 2004;95:104–109. doi: 10.1007/BF03405776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kuo I, Fischer B, Vlahov D. Consideration of a North American heroin-assisted trial for the treatment of opiate-dependent individuals. Int J Drug Policy. 2000;11:357–370. doi: 10.1016/S0955-3959(00)00057-8. [DOI] [PubMed] [Google Scholar]
  • 46.Bammer G, Dobler-Mikola A, Fleming P, Strang J, Uchtenhagen A. The heroin prescribing debate: integrating science and politics. Science. 1999;284:1277–1278. doi: 10.1126/science.284.5418.1277. [DOI] [PubMed] [Google Scholar]
  • 47.Fischer B, Brissette S, Brochu S, et al. Illicit opiate addiction, treatment and policy in Canada: A Cross-Disciplinary, Comprebensive and Concerted Research Initiative 2001. Toronto: Centre for Addiction and Mental Health (CAMH) Submitted to the Canadian Institutes of Health Research (CIHR) for the September 2000 competition.
  • 48.Van Doornum G, Lodder A, Buimer M, van Ameijden E, Bruisten S. Evaluation of Hepatitis C antibody testing in saliva specimens collected by two different systems in comparison with HCV antibody and HCV RNA in serum. J Med Virol. 2001;64:13–20. doi: 10.1002/jmv.1011. [DOI] [PubMed] [Google Scholar]
  • 49.Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry J. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ. 2000;321:78–82. doi: 10.1136/bmj.321.7253.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Ettiegne-Traore V, Ghys P, Maurice C, et al. Evaluation of an HIV saliva test for the detection of HIV-1 and HIV-2 antibodies in high-risk populations in Abidjan, Cote d’Ivoire. Int J STD AIDS. 1998;9:173–174. doi: 10.1258/0956462981921819. [DOI] [PubMed] [Google Scholar]
  • 51.Emmons W. Accuracy of oral specimen testing for human immunodeficiency virus. Am J Med. 1997;102:15–20. doi: 10.1016/S0002-9343(97)00033-8. [DOI] [PubMed] [Google Scholar]
  • 52.Bello P, Pasquier C, Gourney P, Puel J, Izopet J. Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies. Eur J Clin Microbiol Infect Dis. 1998;17:570–572. doi: 10.1007/BF01708621. [DOI] [PubMed] [Google Scholar]
  • 53.Patten S. Performance of the Composite International Diagnostic Interview Short Form for major depression in community and clinical samples. Chronic Dis Can. 1997;18:109–112. [PubMed] [Google Scholar]
  • 53.SPSS 2000, 10.1 for Windows. Chicago: SPSS Inc.
  • 55.National Drug Intelligence Center. Information Bulletin: Oxycontin Diversion and Abuse; 2001. Available at: www.usdoj.gov/ndic/pubs/651. Accessed April 8, 2004.
  • 56.The Fifth Estate. Hillbilly Heroin; 2003. Available at: http://www.cbc.ca/fifth/main_hillbillyheroin.html. Accessed April 8, 2004.
  • 57.Health and Community Services Newfoundland and Labrador. Oxycontin Task Force: Interim Report, 2004. Available at: http://www.gov.nf.ca/health/publications/oxycontininterim/default.htm. Accessed April 8, 2004.
  • 58.Fischer B, Kirst M, Rehm J, Marsh D, Bondy S, Tyndall M. The phenomenon of so-called ‘other drug use’ among opiate addicts in the North American context: evidence, consequences, questions. In: Westermann B, Bellman G, Jellinek C, editors. Beigebrauch: Offene Grenzen der Substitution. Weinheim, Germany: BELTZ Deutscher Studien Verlag; 2000. pp. 95–118. [Google Scholar]
  • 59.Kosten T, Rounsaville B, Kleber H. Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up. J Nerv Ment Dis. 1988;176:176–181. doi: 10.1097/00005053-198803000-00006. [DOI] [PubMed] [Google Scholar]
  • 60.Smyth B, O’Brien M, Barry J. Trends in treated opiate misuse in Dublin: the emergence of chasing the dragon. Addiction. 2000;95:1217–1223. doi: 10.1046/j.1360-0443.2000.95812178.x. [DOI] [PubMed] [Google Scholar]
  • 61.Schottenfeld R, O’Malley S, Abdul-Salaam K, O’Connor P. Decline in intravenous drug use among treatment-seeking opiate users. J Subst Abuse Treat. 1993;10:5–10. doi: 10.1016/0740-5472(93)90092-G. [DOI] [PubMed] [Google Scholar]
  • 62.Strang J, Griffiths P, Powis B, Gossop M. First use of heroin: changes in the route of administration over time. BMJ. 1992;304:1222–1223. doi: 10.1136/bmj.304.6836.1222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Gossop M, Griffiths P, Powis B, Williamson S. Continuing drug risk behaviour: shared use of injecting paraphernalia among London heroin injectors. AIDS Care. 1997;9:651–660. doi: 10.1080/09540129750124687. [DOI] [PubMed] [Google Scholar]
  • 64.Hankins C. Syringe exchange in Canada: good but not enough to stem the HIV tide. Subst Use Misure. 1998;33:1129–1145. doi: 10.3109/10826089809062211. [DOI] [PubMed] [Google Scholar]
  • 65.Drug Users and Studies of HIV/AIDS and Illegal Drugs. Montreal: Canadian HIV/AIDS Legal Network; 1999. [Google Scholar]
  • 66.Haydon E, Fischer B, Rehm J. Social determinants of (illicit) drug use and the HIV/AIDS burden. In: Fischer B, Rehm J, Haydon E, editors. Reducing the Risks, Harms and Costs of HIV/AIDS and Injection Drug Use: A Synthesis of the Evidence Base for Development of Policies and Programs. Warsaw: Health Canada/UNAIDS/Canadian International Development Agency; 2003. [Google Scholar]
  • 67.Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562. doi: 10.1056/NEJM199908193410802. [DOI] [PubMed] [Google Scholar]
  • 68.Seymour A, Oliver J, Black M. Drug-related deaths of recently release prisoners in the Strathclyde Region of Scotland. J Forensic Sci. 2001;45:649–654. [PubMed] [Google Scholar]
  • 69.Noël L, Godin G, Alary M. Processus de marginalisation et risque pour le VIH chez les utilisateurs de drogues par injection. Psychotropes. 2002;8:7–27. [Google Scholar]
  • 70.Kouyanou K, Pither C, Wessely S. Medication misuse, abuse and dependence in chronic pain patients. J Psychosom Res. 1997;43:497–504. doi: 10.1016/S0022-3999(97)00171-2. [DOI] [PubMed] [Google Scholar]
  • 71.Fishbain D. Approaches to treatment decisions for psychiatric comorbidity in the management of the chronic pain patient. Med Clin North Am. 1999;83:737–760. doi: 10.1016/S0025-7125(05)70132-2. [DOI] [PubMed] [Google Scholar]
  • 72.Krausz M, Verthein U, Degkwitz P. Psychiatric comorbidity in opiate addicts. Eur Addict Res. 1999;5:55–62. doi: 10.1159/000018966. [DOI] [PubMed] [Google Scholar]
  • 73.Statistics Canada. Self-rated Health, by Age Group and Sex, Household Population Aged 12 and over, Canada, 2000/01. Available at: http://www.statcan.ca. Accessed April 08, 2004.
  • 74.Alterman A, Rutherford M, Cacciola J, McKay J, Woody G. Response to methadone maintenance and counseling in antisocial patients with and without major depression. J Nerv Ment Dis. 1996;184:695–702. doi: 10.1097/00005053-199611000-00007. [DOI] [PubMed] [Google Scholar]
  • 75.McLellan A, Luborsky L, Woody G, O’Brien C, Druley K. Predicting response to alcohol and drug abuse treatments. Arch Gen Psychiatry. 1983;40:620–625. doi: 10.1001/archpsyc.1983.04390010030004. [DOI] [PubMed] [Google Scholar]
  • 76.Palepu A, Strathdee SA, Hogg RS, et al. The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health. 1999;76:409–418. doi: 10.1007/BF02351499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345:211–214. doi: 10.1056/NEJM200107193450311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Khantzian E. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997;4:231–231. doi: 10.3109/10673229709030550. [DOI] [PubMed] [Google Scholar]
  • 79.Fischer B, Chin A, Kuo I, Kirst M, Vlahov D. Canadian illicit opiate users’ views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse. 2002;37:495–522. doi: 10.1081/JA-120002807. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES